A new Commonwealth Fund study finds that 21% of adults with health insurance spent 5% or more of their income on out-of pocket expenses and that 40% skipped medical treatment because of high deductibles.
A new Commonwealth Fund report finds that 21% of adults with health insurance spent 5% or more of their income on out-of pocket expenses, excluding premiums.
Another 13% spent 10% or more, and low-cost adults were the most likely to have high out-of-pocket costs.
In addition, 13% of people with private health insurance now have plans with a deductible that is equivalent to 5% or more of their income.
The report, Too High a Price: Out-of-Pocket Health Care Costs in the United States, noted that rising deductibles and stagnant family income has led to underinsurance in some cases.
Results were based on a survey of 2,751 adults ages 19 to 64 about the costs of their health insurance.
Insured adults in fair or poor health or those who reported at least one chronic condition were more likely to spend a larger share of their income on medical expenses not covered by insurance.
Other findings:
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 13th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More